ArticleScientific reports2022

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.

Piyada Sitthideatphaiboon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.